Official Title
A Randomized, Multicenter, Double-blind Phase 3 Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease
Brief Summary

Primary Objective: To determine whether Amcenestrant (SAR439859) in combination with palbociclib improves progression free survival (PFS) when compared with letrozole in combination with palbociclib in participants with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have not received any prior systemic anticancer therapies for advanced disease. Secondary Objective: - To compare the overall survival in both treatment arms. - To evaluate the objective response rate in both treatment arms. - To evaluate the duration of response in both treatment arms. - To evaluate the clinical benefit rate in both treatment arms. - To evaluate progression-free survival on next line of therapy. - To evaluate the pharmacokinetics of amcenestrant, and palbociclib. - To evaluate health-related quality of life in both treatment arms. - To evaluate the time to first chemotherapy in both treatment arms. - To evaluate safety in both treatment arms.

Detailed Description

Study duration per participant is approximately 59 months, which includes a 33- month
treatment period.

Terminated
Breast Cancer

Drug: Amcenestrant-matching placebo

Pharmaceutical form: Tablets Route of Administration: Oral

Drug: SAR439859

Pharmaceutical form: Tablets Route of Administration: Oral
Other Name: Amcenestrant

Drug: Palbociclib

Pharmaceutical form: Capsules/Tablets Route of Administration: Oral
Other Name: Ibrance

Drug: Letrozole

Pharmaceutical form: Capsules Route of Administration: Orally

Drug: Goserelin

Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous

Drug: Letrozole-matching placebo

Pharmaceutical form: Capsules Route of Administration: Orally

Eligibility Criteria

Inclusion criteria :

- Adult participants with loco-regional recurrent or metastatic disease not amenable to
curative treatment.

- Confirmed diagnosis of ER+/HER2- breast cancer.

- No prior systemic treatment for loco-regional recurrent or metastatic disease.

- Measurable disease evaluable per Response Evaluation Criterion in Solid Tumors
(RECIST) v.1.1 or non-measurable bone-only disease.

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

- Participants should be willing to provide tumor tissue.

- Capable of giving informed consent.

Exclusion criteria:

- Known active brain metastases.

- Prior neo (adjuvant) treatment with any selective estrogen receptor degrader (SERD).

- Inadequate organ and marrow function.

- Disease recurrence while on, or within 12 months of completion of (neo)adjuvant
endocrine therapy.

- Pregnant, breastfeeding, or woman of childbearing potential unwilling to use
recommended contraception methods.

- Male participants who disagree to follow contraception.

- Participants with advanced, symptomatic visceral spread, that are at risk of
life-threatening complications in the short term.

- Participants with significant concomitant illness.

The above information is not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Canada
Chile
China
Czechia
Finland
France
Georgia
Germany
Hungary
Italy
Japan
Korea, Republic of
Netherlands
Poland
Portugal
Russian Federation
Singapore
South Africa
Spain
Taiwan
Turkey
Ukraine
United Kingdom
United States
Locations

Investigational Site Number :8400075
Daphne, Alabama, United States

Investigational Site Number :8400083
Glendale, Arizona, United States

Investigational Site Number :8400066
Tucson, Arizona, United States

Investigational Site Number :8400038
Fullerton, California, United States

Investigational Site Number :8400056
Los Alamitos, California, United States

Investigational Site Number :8400029
Santa Monica, California, United States

Investigational Site Number :8400025
Denver, Colorado, United States

Investigational Site Number :8400059
Lakeland, Florida, United States

Investigational Site Number :8400053
Orlando, Florida, United States

Investigational Site Number :8400081
Palm Bay, Florida, United States

Investigational Site Number :8400055
Athens, Georgia, United States

Investigational Site Number :8400016
Atlanta, Georgia, United States

Investigational Site Number :8400034
Savannah, Georgia, United States

Investigational Site Number :8400035
Thomasville, Georgia, United States

Investigational Site Number :8400039
Chicago, Illinois, United States

Investigational Site Number :8400008
Fort Wayne, Indiana, United States

Investigational Site Number :8400006
Iowa City, Iowa, United States

Investigational Site Number :8400013
Westwood, Kansas, United States

Investigational Site Number :8400028
Scarborough, Maine, United States

Investigational Site Number :8400017
Boston, Massachusetts, United States

Investigational Site Number :8400076
Danvers, Massachusetts, United States

Investigational Site Number :8400077
Newton, Massachusetts, United States

Investigational Site Number :8400002
Ann Arbor, Michigan, United States

Investigational Site Number :8400005
Kansas City, Missouri, United States

Investigational Site Number :8400004
Saint Louis, Missouri, United States

Investigational Site Number :8400058
Las Vegas, Nevada, United States

Investigational Site Number :8400015
New Brunswick, New Jersey, United States

Investigational Site Number :8400024
Paramus, New Jersey, United States

Investigational Site Number :8400010
New York, New York, United States

Investigational Site Number :8400023
Stony Brook, New York, United States

Investigational Site Number :8400009
Winston-Salem, North Carolina, United States

Investigational Site Number :8400067
Tigard, Oregon, United States

Investigational Site Number :8400001
Pittsburgh, Pennsylvania, United States

Investigational Site Number :8400073
Austin, Texas, United States

Investigational Site Number :8400072
Dallas, Texas, United States

Investigational Site Number :8400070
Dallas, Texas, United States

Investigational Site Number :8400080
Denton, Texas, United States

Investigational Site Number :8400061
Houston, Texas, United States

Investigational Site Number :8400068
Houston, Texas, United States

Investigational Site Number :8400084
Plano, Texas, United States

Investigational Site Number :8400086
The Woodlands, Texas, United States

Investigational Site Number :8400078
Waco, Texas, United States

Investigational Site Number :8400082
Webster, Texas, United States

Investigational Site Number :8400085
Blacksburg, Virginia, United States

Investigational Site Number :8400069
Winchester, Virginia, United States

Investigational Site Number :0320001
Caba, Buenos Aires, Argentina

Investigational Site Number :0320005
Caba, Buenos Aires, Argentina

Investigational Site Number :0320008
Capital Federal, Buenos Aires, Argentina

Investigational Site Number :0320006
Pergamino, Buenos Aires, Argentina

Investigational Site Number :0320010
Cordoba, Córdoba, Argentina

Investigational Site Number :0320002
Rosario, Santa Fe, Argentina

Investigational Site Number :0320004
Buenos Aires, Argentina

Investigational Site Number :0320003
La Rioja, Argentina

Investigational Site Number :0320009
Mar del Plata, Argentina

Investigational Site Number :0320007
Salta, Argentina

Investigational Site Number :0360004
Macquarie Park, New South Wales, Australia

Investigational Site Number :0360005
Randwick, New South Wales, Australia

Investigational Site Number :0360003
Wahroonga, New South Wales, Australia

Investigational Site Number :0360002
Richmond, Victoria, Australia

Investigational Site Number :0360001
Nedlands, Western Australia, Australia

Investigational Site Number :0400001
Graz, Austria

Investigational Site Number :0560003
Bruxelles, Belgium

Investigational Site Number :0560004
Charleroi, Belgium

Investigational Site Number :0560001
Leuven, Belgium

Investigational Site Number :0560002
Namur, Belgium

Investigational Site Number :0760005
Porto Alegre, Rio Grande Do Sul, Brazil

Investigational Site Number :0760006
Porto Alegre, Rio Grande Do Sul, Brazil

Investigational Site Number :0760007
Sao Paulo, São Paulo, Brazil

Investigational Site Number :0760003
Sao Paulo, São Paulo, Brazil

Investigational Site Number :0760004
Rio De Janeiro, Brazil

Investigational Site Number :0760008
São Paulo, Brazil

Investigational Site Number :1000004
Burgas, Bulgaria

Investigational Site Number :1000005
Dobrich, Bulgaria

Investigational Site Number :1000008
Russe, Bulgaria

Investigational Site Number :1000001
Sofia, Bulgaria

Investigational Site Number :1240004
Kingston, Ontario, Canada

Investigational Site Number :1240002
Toronto, Ontario, Canada

Investigational Site Number :1240007
Greenfield Park, Quebec, Canada

Investigational Site Number :1240014
Montreal, Quebec, Canada

Investigational Site Number :1240005
Montreal, Quebec, Canada

Investigational Site Number :1520005
La Serena, Coquimbo, Chile

Investigational Site Number :1520004
Temuco, La Araucanía, Chile

Investigational Site Number :1520009
Talca, Maule, Chile

Investigational Site Number :1520011
Santaigo, Reg Metropolitana De Santiago, Chile

Investigational Site Number :1520006
Santiago, Reg Metropolitana De Santiago, Chile

Investigational Site Number :1520002
Santiago, Reg Metropolitana De Santiago, Chile

Investigational Site Number :1520001
Viña del Mar, Valparaíso, Chile

Investigational Site Number :1520003
Santiago de Chile, Chile

Investigational Site Number :1520007
Santiago, Chile

Investigational Site Number :1560038
Baoding, China

Investigational Site Number :1560008
Beijing, China

Investigational Site Number :1560035
Beijing, China

Investigational Site Number :1560003
Changchun, China

Investigational Site Number :1560036
Changchun, China

Investigational Site Number :1560013
Chengdu, China

Investigational Site Number :1560019
Chongqing, China

Investigational Site Number :1560031
Dalian, China

Investigational Site Number :1560021
Dalian, China

Investigational Site Number :1560054
Deyang, China

Investigational Site Number :1560043
Fuzhou, China

Investigational Site Number :1560025
Guangzhou, China

Investigational Site Number :1560006
Hangzhou, China

Investigational Site Number :1560007
Hangzhou, China

Investigational Site Number :1560002
Hangzhou, China

Investigational Site Number :1560005
Hangzhou, China

Investigational Site Number :1560011
Harbin, China

Investigational Site Number :1560041
Hefei, China

Investigational Site Number :1560018
Jinan, China

Investigational Site Number :1560046
Jinan, China

Investigational Site Number :1560051
Jining, China

Investigational Site Number :1560017
Linyi, China

Investigational Site Number :1560055
Luoyang, China

Investigational Site Number :1560048
Neijiang, China

Investigational Site Number :1560001
Shanghai, China

Investigational Site Number :1560037
Shaoguan, China

Investigational Site Number :1560028
Tianjin, China

Investigational Site Number :1560033
Wuhan, China

Investigational Site Number :1560024
Wuhan, China

Investigational Site Number :1560045
Xi'an, China

Investigational Site Number :1560044
Xi'An, China

Investigational Site Number :1560027
Xuzhou, China

Investigational Site Number :1560049
Yantai, China

Investigational Site Number :1560022
Zhengzhou, China

Investigational Site Number :2030001
Brno, Czechia

Investigational Site Number :2030002
Praha 2, Czechia

Investigational Site Number :2460001
Helsinki, Finland

Investigational Site Number :2460002
Tampere, Finland

Investigational Site Number :2460003
Turku, Finland

Investigational Site Number :2500009
Nice, France

Investigational Site Number :2500003
Paris, France

Investigational Site Number :2500001
Paris, France

Investigational Site Number :2500006
Poitiers, France

Investigational Site Number :2500007
Saint Cloud, France

Investigational Site Number :2500002
Saint-Herblain, France

Investigational Site Number :2500010
Strasbourg, France

Investigational Site Number :2500005
TOULOUSE Cedex 9, France

Investigational Site Number :2500004
Villejuif, France

Investigational Site Number :2680005
Batumi, Georgia

Investigational Site Number :2680006
Kutaisi, Georgia

Investigational Site Number :2680001
Tbilisi, Georgia

Investigational Site Number :2680002
Tbilisi, Georgia

Investigational Site Number :2680004
Tbilisi, Georgia

Investigational Site Number :2680007
Tbilisi, Georgia

Investigational Site Number :2680003
Tbilisi, Georgia

Investigational Site Number :2760006
Bottrop, Germany

Investigational Site Number :2760003
Münster, Germany

Investigational Site Number :2760007
Oldenburg in Holstein, Germany

Investigational Site Number :2760001
Ulm, Germany

Investigational Site Number :3480008
Budapest, Hungary

Investigational Site Number :3480011
Gyula, Hungary

Investigational Site Number :3480005
Győr, Hungary

Investigational Site Number :3480003
Kaposvár, Hungary

Investigational Site Number :3480009
Kecskemét, Hungary

Investigational Site Number :3480010
Miskolc, Hungary

Investigational Site Number :3480001
Nyíregyháza, Hungary

Investigational Site Number :3800008
Meldola (FC), Emilia-Romagna, Italy

Investigational Site Number :3800003
Rozzano, Milano, Italy

Investigational Site Number :3800007
Monza, Monza E Brianza, Italy

Investigational Site Number :3800010
Bologna, Italy

Investigational Site Number :3800004
Milano, Italy

Investigational Site Number :3800002
Milano, Italy

Investigational Site Number :3800006
Napoli, Italy

Investigational Site Number :3800005
Prato, Italy

Investigational Site Number :3920016
Nagoya-shi, Aichi, Japan

Investigational Site Number :3920007
Nagoya-shi, Aichi, Japan

Investigational Site Number :3920002
Kashiwa-shi, Chiba, Japan

Investigational Site Number :3920009
Matsuyama-shi, Ehime, Japan

Investigational Site Number :3920019
Kurume-shi, Fukuoka, Japan

Investigational Site Number :3920017
Takasaki-shi, Gunma, Japan

Investigational Site Number :3920010
Hiroshima-shi, Hiroshima, Japan

Investigational Site Number :3920001
Sapporo-shi, Hokkaido, Japan

Investigational Site Number :3920012
Kagoshima-shi, Kagoshima, Japan

Investigational Site Number :3920014
Yokohama-shi, Kanagawa, Japan

Investigational Site Number :3920006
Yokohama-shi, Kanagawa, Japan

Investigational Site Number :3920020
Sendai-shi, Miyagi, Japan

Investigational Site Number :3920022
Miyazaki-shi, Miyazaki, Japan

Investigational Site Number :3920008
Osaka-shi, Osaka, Japan

Investigational Site Number :3920018
Osaka-shi, Osaka, Japan

Investigational Site Number :3920013
Hidaka-shi, Saitama, Japan

Investigational Site Number :3920021
Shizuoka-shi, Shizuoka, Japan

Investigational Site Number :3920003
Koto-ku, Tokyo, Japan

Investigational Site Number :3920015
Meguro-ku, Tokyo, Japan

Investigational Site Number :3920005
Shinagawa-ku, Tokyo, Japan

Investigational Site Number :4100006
Goyang-si, Gyeonggi-do, Korea, Republic of

Investigational Site Number :4100005
Seongnam, Gyeonggi-do, Korea, Republic of

Investigational Site Number :4100007
Seoul, Seoul-teukbyeolsi, Korea, Republic of

Investigational Site Number :4100004
Seoul, Seoul-teukbyeolsi, Korea, Republic of

Investigational Site Number :4100003
Seoul, Seoul-teukbyeolsi, Korea, Republic of

Investigational Site Number :4100002
Seoul, Seoul-teukbyeolsi, Korea, Republic of

Investigational Site Number :4100001
Seoul, Seoul-teukbyeolsi, Korea, Republic of

Investigational Site Number :4100009
Seochogu, Korea, Republic of

Investigational Site Number :4100008
Seongnam-si, Gyeonggi-do, Korea, Republic of

Investigational Site Number :5280006
Arnhem, Netherlands

Investigational Site Number :5280005
Delft, Netherlands

Investigational Site Number :5280001
Maastricht, Netherlands

Investigational Site Number :6160002
Tomaszow Mazowiecki, Lódzkie, Poland

Investigational Site Number :6160007
Poznan, Wielkopolskie, Poland

Investigational Site Number :6200005
Almada, Portugal

Investigational Site Number :6200001
Lisboa, Portugal

Investigational Site Number :6200002
Porto, Portugal

Investigational Site Number :6430007
Arkhangelsk, Russian Federation

Investigational Site Number :6430004
Krasnogorskiy District, Russian Federation

Investigational Site Number :6430009
Moscow Region, Russian Federation

Investigational Site Number :6430008
Moscow, Russian Federation

Investigational Site Number :6430003
Moscow, Russian Federation

Investigational Site Number :6430005
Moscow, Russian Federation

Investigational Site Number :6430006
Moscow, Russian Federation

Investigational Site Number :6430001
Saint -Petersburg, Russian Federation

Investigational Site Number :6430010
Saint Petersburg, Russian Federation

Investigational Site Number :7020002
Singapore, Singapore

Investigational Site Number :7020004
Singapore, Singapore

Investigational Site Number :7020001
Singapore, Singapore

Investigational Site Number :7100004
Cape Town, South Africa

Investigational Site Number :7100006
Johannesburg, South Africa

Investigational Site Number :7240011
Barcelona, Barcelona [Barcelona], Spain

Investigational Site Number :7240008
Barcelona / Sabadell, Castilla Y León, Spain

Investigational Site Number :7240003
Santiago de Compostela, Galicia [Galicia], Spain

Investigational Site Number :7240006
Madrid / Madrid, Madrid, Comunidad De, Spain

Investigational Site Number :7240002
Madrid / Madrid, Madrid, Comunidad De, Spain

Investigational Site Number :7240004
Madrid, Madrid, Comunidad De, Spain

Investigational Site Number :7240005
Valencia, Valenciana, Comunidad, Spain

Investigational Site Number :7240001
Madrid, Spain

Investigational Site Number :7240007
Málaga, Spain

Investigational Site Number :7240009
Valencia, Spain

Investigational Site Number :1580007
Kaohsiung, Taiwan

Investigational Site Number :1580002
Tainan, Taiwan

Investigational Site Number :1580001
Taipei, Taiwan

Investigational Site Number :1580003
Taipei, Taiwan

Investigational Site Number :7920006
Adana, Turkey

Investigational Site Number :7920008
Ankara, Turkey

Investigational Site Number :7920009
Ankara, Turkey

Investigational Site Number :7920007
Antalya, Turkey

Investigational Site Number :7920005
Bornova, Turkey

Investigational Site Number :7920013
Diyarbakır, Turkey

Investigational Site Number :7920003
Edirne, Turkey

Investigational Site Number :7920001
Istanbul, Turkey

Investigational Site Number :7920011
Istanbul, Turkey

Investigational Site Number :7920004
Istanbul, Turkey

Investigational Site Number :7920012
İzmir, Turkey

Investigational Site Number :7920010
Kocaeli, Turkey

Investigational Site Number :7920002
Malatya, Turkey

Investigational Site Number :8040004
Kharkiv, Ukraine

Investigational Site Number :8040010
Kharkiv, Ukraine

Investigational Site Number :8040001
Kryvyi Rih, Ukraine

Investigational Site Number :8040002
Odesa, Ukraine

Investigational Site Number :8040007
Vinnytsia, Ukraine

Investigational Site Number :8260001
Glasgow, Central Bedfordshire, United Kingdom

Investigational Site Number :8260002
Edinburgh, Edinburgh, City Of, United Kingdom

Investigational Site Number :8260005
Blackburn, Lancashire, United Kingdom

Clinical Sciences & Operations, Study Director
Sanofi

NCT Number
MeSH Terms
Breast Neoplasms
Letrozole
Palbociclib
Goserelin